Molecular genetics of prostate cancer: new prospects for old challenges.

Despite much recent progress, prostate cancer continues to represent a major cause of cancer-related mortality and morbidity in men. Since early studies on the role of the androgen receptor that led to the advent of androgen deprivation therapy in the 1940s, there has long been intensive interest in the basic mechanisms underlying prostate cancer initiation and progression, as well as the potential to target these processes for therapeutic intervention. Here, we present an overview of major themes in prostate cancer research, focusing on current knowledge of principal events in cancer initiation and progression. We discuss recent advances, including new insights into the mechanisms of castration resistance, identification of stem cells and tumor-initiating cells, and development of mouse models for preclinical evaluation of novel therapuetics. Overall, we highlight the tremendous research progress made in recent years, and underscore the challenges that lie ahead.

[1]  E. Montgomery,et al.  NKX3.1 as a Marker of Prostatic Origin in Metastatic Tumors , 2010, The American journal of surgical pathology.

[2]  Jiaoti Huang,et al.  Identification of a Cell of Origin for Human Prostate Cancer , 2010, Science.

[3]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[4]  Martin J. Aryee,et al.  Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements , 2010, Nature Genetics.

[5]  M. Ittmann,et al.  Dicer Ablation Impairs Prostate Stem Cell Activity and Causes Prostate Atrophy , 2010, Stem cells.

[6]  Francesca Demichelis,et al.  Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.

[7]  R. Silverman,et al.  The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome , 2010, Nature Reviews Urology.

[8]  P. Pandolfi,et al.  A coding-independent function of gene and pseudogene mRNAs regulates tumour biology , 2010, Nature.

[9]  David E. Williams,et al.  Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. , 2010, Cancer cell.

[10]  M. Loda,et al.  A constitutively activated form of the p110β isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice , 2010, Proceedings of the National Academy of Sciences.

[11]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[12]  A. D. De Marzo,et al.  The role of PI 3‐kinase p110β in AKT signally, cell survival, and proliferation in human prostate cancer cells , 2010, The Prostate.

[13]  A. Malek,et al.  ETS Transcription Factors Control Transcription of EZH2 and Epigenetic Silencing of the Tumor Suppressor Gene Nkx3.1 in Prostate Cancer , 2010, PloS one.

[14]  C. Bieberich,et al.  Epithelial and Mesenchymal Cell Biology Loss of Nkx 3 . 1 Expression in Bacterial Prostatitis A Potential Link Between Inflammation and Neoplasia , 2010 .

[15]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[16]  E. Gelmann,et al.  NKX3.1 activates cellular response to DNA damage. , 2010, Cancer research.

[17]  M. Loda,et al.  Identification of the miR-106b~25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation , 2010, Science Signaling.

[18]  P. Pandolfi,et al.  Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence , 2010, Nature.

[19]  Clifford A. Meyer,et al.  Nucleosome Dynamics Define Transcriptional Enhancers , 2010, Nature Genetics.

[20]  Rameen Beroukhim,et al.  An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB , 2010, Nature Medicine.

[21]  A. D'Amico,et al.  American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.

[22]  J. Clohessy,et al.  A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. , 2010, The Journal of clinical investigation.

[23]  D. Bonci,et al.  MicroRNAs and prostate cancer. , 2010, Endocrine-related cancer.

[24]  C. Bieberich,et al.  MYC Overexpression Induces Prostatic Intraepithelial Neoplasia and Loss of Nkx3.1 in Mouse Luminal Epithelial Cells , 2010, PloS one.

[25]  J. Carpten,et al.  Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans , 2010, The Prostate.

[26]  M. Morse,et al.  A year of successful cancer vaccines points to a path forward. , 2010, Current opinion in molecular therapeutics.

[27]  J. Epstein An update of the Gleason grading system. , 2010, The Journal of urology.

[28]  A. Taille,et al.  Urine biomarkers in prostate cancer , 2010, Nature Reviews Urology.

[29]  Hongling Liao,et al.  Long-range enhancers on 8q24 regulate c-Myc , 2010, Proceedings of the National Academy of Sciences.

[30]  S. Memarzadeh,et al.  Basal epithelial stem cells are efficient targets for prostate cancer initiation , 2010, Proceedings of the National Academy of Sciences.

[31]  O. Franco,et al.  Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma , 2010, Oncogene.

[32]  Wei Keat Lim,et al.  The transcriptional network for mesenchymal transformation of brain tumors , 2009, Nature.

[33]  S. Hayward,et al.  Functional Remodeling of Benign Human Prostatic Tissues In Vivo by Spontaneously Immortalized Progenitor and Intermediate Cells , 2009, Stem cells.

[34]  H. Bonkhoff,et al.  From pathogenesis to prevention of castration resistant prostate cancer , 2010, The Prostate.

[35]  Jie Zhang,et al.  Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer , 2009, Cell.

[36]  C. Cooper,et al.  Steroid hormone receptors in prostate cancer: a hard habit to break? , 2009, Cancer cell.

[37]  S. Varambally,et al.  Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer , 2009, Science.

[38]  O. Witte,et al.  Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. , 2009, Cancer research.

[39]  J. Visvader,et al.  Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. , 2009, Genes & development.

[40]  E. Casanova,et al.  A Probasin‐MerCreMer BAC allows inducible recombination in the mouse prostate , 2009, Genesis.

[41]  W. Isaacs,et al.  TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinoma , 2009, Modern Pathology.

[42]  R. Hauke,et al.  Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate , 2009, British Journal of Cancer.

[43]  Lin Lin,et al.  Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. , 2009, Cancer cell.

[44]  H. Scher,et al.  Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. , 2009, The Lancet. Oncology.

[45]  Ali Amin Al Olama,et al.  Multiple loci on 8q24 associated with prostate cancer susceptibility , 2009, Nature Genetics.

[46]  Ali Amin Al Olama,et al.  Identification of seven new prostate cancer susceptibility loci through a genome-wide association study , 2009, Nature Genetics.

[47]  Kari Stefansson,et al.  Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility , 2009, Nature Genetics.

[48]  Peter Kraft,et al.  Identification of a new prostate cancer susceptibility locus on chromosome 8q24 , 2009, Nature Genetics.

[49]  Robert Schlaberg,et al.  XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors , 2009, Proceedings of the National Academy of Sciences.

[50]  S. Koul,et al.  Oxidative stress in prostate cancer. , 2009, Cancer letters.

[51]  Dirk F Moore,et al.  Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.

[52]  S. Morrison,et al.  Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution , 2009, Cell.

[53]  W. Bushman,et al.  The Sonic Hedgehog Pathway Stimulates Prostate Tumor Growth by Paracrine Signaling and Recaptures Embryonic Gene Expression in Tumor Myofibroblasts , 2009, Oncogene.

[54]  M. Loda,et al.  Differential p53-Independent Outcomes of p19Arf Loss in Oncogenesis , 2009, Science Signaling.

[55]  M. Shen,et al.  A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.

[56]  E. Platz,et al.  Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. , 2009, Current opinion in pharmacology.

[57]  B. Trock,et al.  Individual and cumulative effect of prostate cancer risk‐associated variants on clinicopathologic variables in 5,895 prostate cancer patients , 2009, The Prostate.

[58]  W. Gerald,et al.  NF-kappaB regulates androgen receptor expression and prostate cancer growth. , 2009, The American journal of pathology.

[59]  F. Saad,et al.  PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.

[60]  H. Scher,et al.  Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer , 2009, Clinical Cancer Research.

[61]  D. Reich,et al.  Functional Enhancers at the Gene-Poor 8q24 Cancer-Linked Locus , 2009, PLoS genetics.

[62]  M. Teitell,et al.  ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells , 2009, Proceedings of the National Academy of Sciences.

[63]  Clifford A. Meyer,et al.  Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.

[64]  P. Kantoff,et al.  Evaluation of the 8q24 prostate cancer risk locus and MYC expression. , 2009, Cancer research.

[65]  S. Abdulkadir,et al.  Interactions between Cells with Distinct Mutations in c-MYC and Pten in Prostate Cancer , 2009, PLoS genetics.

[66]  Jeffrey M. Rosen,et al.  The Increasing Complexity of the Cancer Stem Cell Paradigm , 2009, Science.

[67]  P. Humphrey,et al.  Loss-of-Nkx3.1 Leads to Activation of Discrete Downstream Target Genes during Prostate Tumorigenesis , 2009, Oncogene.

[68]  Mustafa Ozen,et al.  Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer , 2009, Clinical Cancer Research.

[69]  D. Olmos,et al.  Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. , 2009, Cancer research.

[70]  A. D. De Marzo,et al.  Epigenetic alterations in human prostate cancers. , 2009, Endocrinology.

[71]  M. D. Anway,et al.  Gene expression changes are age‐dependent and lobe‐specific in the brown Norway rat model of prostatic hyperplasia , 2009, The Prostate.

[72]  T. H. van der Kwast,et al.  Accumulating Progenitor Cells in the Luminal Epithelial Cell Layer Are Candidate Tumor Initiating Cells in a Pten Knockout Mouse Prostate Cancer Model , 2009, PloS one.

[73]  C. Takimoto,et al.  Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes , 2009, Clinical Cancer Research.

[74]  S. Dhanasekaran,et al.  Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. , 2009, Cancer research.

[75]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[76]  C. Tepper,et al.  MicroRNAs and their potential for translation in prostate cancer. , 2009, Urologic oncology.

[77]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[78]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[79]  G. Prins,et al.  The role of Wnt5a in prostate gland development. , 2009, Developmental biology.

[80]  Myles Brown,et al.  The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. , 2009, Cancer research.

[81]  Jun Luo,et al.  Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.

[82]  Zhiyong Guo,et al.  Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. , 2009, Cancer cell.

[83]  Carmela Conte,et al.  Oxidative stress-related aging: A role for prostate cancer? , 2009, Biochimica et biophysica acta.

[84]  D. Dearnaley,et al.  Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.

[85]  Oscar Lin,et al.  Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer , 2009, Clinical Cancer Research.

[86]  Zhiyong Guo,et al.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.

[87]  E. Gelmann,et al.  NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation. , 2009, Cancer research.

[88]  David M. Sabatini,et al.  Tumours with PI3K activation are resistant to dietary restriction , 2009, Nature.

[89]  Yi Qu,et al.  Genome-Wide Profiling of Histone H3 Lysine 4 and Lysine 27 Trimethylation Reveals an Epigenetic Signature in Prostate Carcinogenesis , 2009, PloS one.

[90]  Madhuchhanda Bhattacharjee,et al.  Conserved gene expression programs integrate mammalian prostate development and tumorigenesis. , 2009, Cancer research.

[91]  Todd M Morgan,et al.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. , 2009, Current cancer drug targets.

[92]  R. Matusik,et al.  Activation of β‐Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration , 2009, The Prostate.

[93]  M. Karin,et al.  Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2009, Nature.

[94]  J. Céraline,et al.  Pleiotropic functional properties of androgen receptor mutants in prostate cancer , 2009, Human mutation.

[95]  K. Polyak,et al.  Cancer stem cells: a model in the making. , 2009, Current opinion in genetics & development.

[96]  G. Evan,et al.  Cellular senescence: hot or what? , 2009, Current opinion in genetics & development.

[97]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[98]  D. Guertin,et al.  mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.

[99]  J. Crowley,et al.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2009, JAMA.

[100]  H. Fuse,et al.  Neuroendocrine differentiation in the progression of prostate cancer , 2009, International journal of urology : official journal of the Japanese Urological Association.

[101]  A. Clarke,et al.  K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. , 2009, Cancer research.

[102]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[103]  O. Witte,et al.  Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics , 2008, Proceedings of the National Academy of Sciences.

[104]  L. Chin,et al.  BRAF Activation Initiates but Does Not Maintain Invasive Prostate Adenocarcinoma , 2008, PloS one.

[105]  S. Varambally,et al.  Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.

[106]  K. Leong,et al.  Generation of a prostate from a single adult stem cell , 2008, Nature.

[107]  S. Dhanasekaran,et al.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.

[108]  G Parmigiani,et al.  Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer , 2008, Oncogene.

[109]  Mark A Rubin,et al.  Evaluating localized prostate cancer and identifying candidates for focal therapy. , 2008, Urology.

[110]  P. Verhagen,et al.  An activating mutation in AKT1 in human prostate cancer , 2008, International journal of cancer.

[111]  Gang Wang,et al.  Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. , 2008, Cancer research.

[112]  P. Clark,et al.  Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy , 2008, Clinical Cancer Research.

[113]  Mauro Biffoni,et al.  The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities , 2008, Nature Medicine.

[114]  S. Morrison,et al.  Efficient tumor formation by single human melanoma cells , 2008, Nature.

[115]  M. Ittmann,et al.  Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. , 2008, Cancer research.

[116]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[117]  W. Sellers,et al.  Drug discovery approaches targeting the PI3K/Akt pathway in cancer , 2008, Oncogene.

[118]  W. Gerald,et al.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. , 2008, The Journal of clinical investigation.

[119]  E. Gelmann,et al.  Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1. , 2008, Cancer research.

[120]  Jun Luo,et al.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.

[121]  S. Yeh,et al.  Targeting the stromal androgen receptor in primary prostate tumors at earlier stages , 2008, Proceedings of the National Academy of Sciences.

[122]  Jorge Yao,et al.  Androgen receptor is a tumor suppressor and proliferator in prostate cancer , 2008, Proceedings of the National Academy of Sciences.

[123]  W. Gerald,et al.  Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. , 2008, Genes & development.

[124]  S. Kasper,et al.  Stem cells: The root of prostate cancer? , 2008, Journal of cellular physiology.

[125]  I. Mills,et al.  Alterations in β‐catenin expression and localization in prostate cancer , 2008, The Prostate.

[126]  Chen Sun,et al.  Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer , 2008, Clinical Cancer Research.

[127]  R. Stephens,et al.  Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. , 2008, Cancer research.

[128]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[129]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[130]  M. Day,et al.  The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis , 2008, Oncogene.

[131]  B. Trask,et al.  Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. , 2008, Cancer research.

[132]  B. Timms Prostate development: a historical perspective. , 2008, Differentiation; research in biological diversity.

[133]  P. Nelson,et al.  Gene expression profiling in the developing prostate. , 2008, Differentiation; research in biological diversity.

[134]  G. Prins,et al.  Molecular signaling pathways that regulate prostate gland development. , 2008, Differentiation; research in biological diversity.

[135]  O. Franco,et al.  Gene targeting to the stroma of the prostate and bone. , 2008, Differentiation; research in biological diversity.

[136]  G. Cunha Mesenchymal-epithelial interactions: past, present, and future. , 2008, Differentiation; research in biological diversity.

[137]  F. D. D. Fagagna Living on a break: cellular senescence as a DNA-damage response , 2008, Nature Reviews Cancer.

[138]  E. Gelmann,et al.  R E V Ie W a Rt I C L E , 2022 .

[139]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[140]  M. Loda,et al.  Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis , 2008, Nature.

[141]  John T. Wei,et al.  The role of SPINK1 in ETS rearrangement-negative prostate cancers. , 2008, Cancer cell.

[142]  N. Maitland,et al.  Prostate cancer stem cells: a new target for therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  Ian A. White,et al.  CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. , 2008, The Journal of clinical investigation.

[144]  D. Gold,et al.  Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation , 2008, Nature Genetics.

[145]  J. Ting,et al.  Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. , 2008, Genes & development.

[146]  T. Tammela,et al.  TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis , 2008, Clinical Cancer Research.

[147]  M. Loda,et al.  Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications , 2008, Clinical Cancer Research.

[148]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[149]  A. Strasser,et al.  Is tumor growth sustained by rare cancer stem cells or dominant clones? , 2008, Cancer research.

[150]  R. Shah,et al.  Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. , 2008, Cancer research.

[151]  M. Parker,et al.  Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression , 2008, Oncogene.

[152]  Pier Paolo Pandolfi,et al.  Tenets of PTEN Tumor Suppression , 2008, Cell.

[153]  R. Silverman,et al.  Inflammation, infection, and prostate cancer , 2008, Current opinion in urology.

[154]  J. Amiel,et al.  Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. , 2008, Cancer genetics and cytogenetics.

[155]  Hua Tian,et al.  A paracrine requirement for hedgehog signalling in cancer , 2008, Nature.

[156]  S. Jones,et al.  Many roads lead to oncogene-induced senescence , 2008, Oncogene.

[157]  M. Shen,et al.  Sox9 is required for prostate development. , 2008, Developmental biology.

[158]  D. Elashoff,et al.  Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. , 2008, Cancer research.

[159]  R. Shah,et al.  CHARACTERIZATION OF TMPRSS2-ETS GENE ABERRATIONS IN ANDROGEN INDEPENDENT METASTATIC PROSTATE CANCER , 2008 .

[160]  S. Signoretti,et al.  p63 in prostate biology and pathology , 2008, Journal of cellular biochemistry.

[161]  F. Jirik,et al.  Temporally controlled prostate epithelium‐specific gene alterations , 2008, Genesis.

[162]  T. Ratliff,et al.  Prostate inflammation and its potential impact on prostate cancer: A current review , 2008, Journal of cellular biochemistry.

[163]  Andrew J. Vickers,et al.  Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.

[164]  J. Cuzick,et al.  Complex patterns of ETS gene alteration arise during cancer development in the human prostate , 2008, Oncogene.

[165]  C. Creighton,et al.  Widespread deregulation of microRNA expression in human prostate cancer , 2008, Oncogene.

[166]  W. Willett,et al.  Multiple loci identified in a genome-wide association study of prostate cancer , 2008, Nature Genetics.

[167]  P. Chambon,et al.  Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma , 2008, Proceedings of the National Academy of Sciences.

[168]  S. Cross,et al.  The polycomb group protein EZH2 regulates actin polymerization in human prostate cancer cells , 2008, The Prostate.

[169]  W. Isaacs,et al.  A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms , 2008, The Prostate.

[170]  M. Shen,et al.  Role of epithelial cell fibroblast growth factor receptor substrate 2α in prostate development, regeneration and tumorigenesis , 2008, Development.

[171]  P. Nelson,et al.  A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.

[172]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[173]  Alastair Droop,et al.  Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions , 2008, Genome Biology.

[174]  Christopher P Evans,et al.  An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells , 2007, Proceedings of the National Academy of Sciences.

[175]  M. Teitell,et al.  Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. , 2007, Cancer cell.

[176]  Leif E. Peterson,et al.  Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. , 2007, Cancer cell.

[177]  Oliver Sartor,et al.  Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. , 2007, The Journal of urology.

[178]  K. Fizazi,et al.  The role of Src in prostate cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[179]  A. Zlotta,et al.  Prostate cancer prevention , 2007, Cancer.

[180]  Li Li,et al.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.

[181]  B. Aronow,et al.  Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. , 2007, Cancer research.

[182]  M. Kattan,et al.  Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.

[183]  R. Schneider-Broussard,et al.  Erratum: Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+α2β1+ cell population is enriched in tumor-initiating cells (Cancer Research (2007) 67, (6796-6805)) , 2007 .

[184]  J. Brooks,et al.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.

[185]  R. Shah,et al.  Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. , 2007, Cancer research.

[186]  M. Papotti,et al.  Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. , 2007, The Journal of urology.

[187]  A. D. De Marzo,et al.  Inflammation, atrophy, and prostate carcinogenesis. , 2007, Urologic oncology.

[188]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[189]  Ming-Fong Lin,et al.  Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. , 2007, Endocrine-related cancer.

[190]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[191]  E. Small,et al.  Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge®) , 2007, Expert opinion on biological therapy.

[192]  O. Witte,et al.  Stem cells in prostate cancer initiation and progression. , 2007, The Journal of clinical investigation.

[193]  Wei Shi,et al.  Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. , 2007, Cancer research.

[194]  S. Yeh,et al.  Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor , 2007, Proceedings of the National Academy of Sciences.

[195]  R. Schneider-Broussard,et al.  Hierarchical Organization of Prostate Cancer Cells in Xenograft Tumors: The CD44+α2β1+ Cell Population Is Enriched in Tumor-Initiating Cells , 2007 .

[196]  M. Shen,et al.  Pten inactivation and the emergence of androgen-independent prostate cancer. , 2007, Cancer research.

[197]  Mikhail Teverovskiy,et al.  Improved prediction of prostate cancer recurrence through systems pathology. , 2007, The Journal of clinical investigation.

[198]  H. Zhang,et al.  Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. , 2007, The Journal of clinical investigation.

[199]  Jayoung Kim,et al.  Cholesterol sensitivity of endogenous and myristoylated Akt. , 2007, Cancer research.

[200]  Shunyou Wang,et al.  Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. , 2007, Cancer research.

[201]  T. Tammela,et al.  MicroRNA expression profiling in prostate cancer. , 2007, Cancer research.

[202]  F. Ishikawa,et al.  Cellular senescence and chromatin structure , 2007, Chromosoma.

[203]  Debashis Ghosh,et al.  Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer , 2007, Modern Pathology.

[204]  M. Rubin,et al.  Morphological features of TMPRSS2–ERG gene fusion prostate cancer , 2007, The Journal of pathology.

[205]  A. D. De Marzo,et al.  Abnormal DNA methylation, epigenetics, and prostate cancer. , 2007, Frontiers in bioscience : a journal and virtual library.

[206]  D. Gudbjartsson,et al.  Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 , 2007, Nature Genetics.

[207]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[208]  R. Eeles,et al.  Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.

[209]  David A. Cheresh,et al.  Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2007, Nature.

[210]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[211]  A. Whittemore,et al.  Multiple regions within 8q24 independently affect risk for prostate cancer , 2007, Nature Genetics.

[212]  N. Rosen,et al.  Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor , 2007, Molecular and Cellular Endocrinology.

[213]  J. Mossong,et al.  Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis , 2007, International journal of cancer.

[214]  J. Resau,et al.  Inactivation of Apc in the mouse prostate causes prostate carcinoma. , 2007, Cancer research.

[215]  M. Shen,et al.  Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis , 2007, Development.

[216]  A. D. De Marzo,et al.  The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. , 2007, Cancer research.

[217]  J. Derisi,et al.  An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors , 2007, Proceedings of the National Academy of Sciences.

[218]  O. Witte,et al.  Isolation and functional characterization of murine prostate stem cells , 2007, Proceedings of the National Academy of Sciences.

[219]  P. Humphrey,et al.  Diagnosis of adenocarcinoma in prostate needle biopsy tissue , 2007, Journal of Clinical Pathology.

[220]  John T. Wei,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007, Nature Genetics.

[221]  D. Petrylak New paradigms for advanced prostate cancer. , 2007, Reviews in urology.

[222]  C. Sternberg,et al.  Current indications for chemotherapy in prostate cancer patients. , 2007, European urology.

[223]  A. Evans,et al.  Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer. , 2007, Neoplasia.

[224]  D. Schrijvers Androgen-independent prostate cancer. , 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[225]  W. Zhong,et al.  Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis , 2007, The Prostate.

[226]  C. Bieberich,et al.  Decreased NKX3.1 Protein Expression in Focal Prostatic Atrophy, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma: Association with Gleason Score and Chromosome 8p Deletion , 2006 .

[227]  T. Vomastek,et al.  Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. , 2006, Cancer research.

[228]  O. Kallioniemi,et al.  TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. , 2006, Cancer research.

[229]  R. Schwartz,et al.  Expression of an Nkx3.1‐CRE gene using ROSA26 reporter mice , 2006, Genesis.

[230]  Rajiv Dhir,et al.  Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. , 2006, The American journal of pathology.

[231]  B. Tai,et al.  RNASEL Gene Polymorphisms and the Risk of Prostate Cancer: a Meta-analysis , 2006, Clinical Cancer Research.

[232]  L. Lessard,et al.  Nuclear Localization of Nuclear Factor-κB p65 in Primary Prostate Tumors Is Highly Predictive of Pelvic Lymph Node Metastases , 2006, Clinical Cancer Research.

[233]  Jiaoti Huang,et al.  Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression , 2006, Modern Pathology.

[234]  R. DiPaola,et al.  Vitamin D Inhibits the Formation of Prostatic Intraepithelial Neoplasia in Nkx3.1; Pten Mutant Mice , 2006, Clinical Cancer Research.

[235]  Zhiyong Guo,et al.  Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.

[236]  W. Gerald,et al.  Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer , 2006, Proceedings of the National Academy of Sciences.

[237]  A. Whittemore,et al.  Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men , 2006, Proceedings of the National Academy of Sciences.

[238]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[239]  Michael Ittmann,et al.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.

[240]  David C. Corney,et al.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.

[241]  M. Shen,et al.  Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. , 2006, Cancer research.

[242]  Leroy Hood,et al.  A molecular correlate to the Gleason grading system for prostate adenocarcinoma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[243]  Tapio Visakorpi,et al.  The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer , 2006, Genes, chromosomes & cancer.

[244]  M. Conaway,et al.  Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells , 2006, The Prostate.

[245]  R. Lipinski,et al.  Functional compensation in Hedgehog signaling during mouse prostate development. , 2006, Developmental biology.

[246]  P. Pandolfi,et al.  p18Ink4c and Pten Constrain a Positive Regulatory Loop between Cell Growth and Cell Cycle Control , 2006, Molecular and Cellular Biology.

[247]  M. Gleave,et al.  Loss of PTEN is associated with progression to androgen independence , 2006, The Prostate.

[248]  R. Cardiff,et al.  Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. , 2006, Neoplasia.

[249]  A. Gylfason,et al.  A common variant associated with prostate cancer in European and African populations , 2006, Nature Genetics.

[250]  E. Hurt,et al.  Stem cells in prostate cancer: Resolving the castrate-resistant conundrum and implications for hormonal therapy , 2006, Cancer biology & therapy.

[251]  Jason A. Koutcher,et al.  Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.

[252]  I. Mellinghoff,et al.  Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[253]  M. Gleave,et al.  NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. , 2006, Cancer cell.

[254]  H. Stoop,et al.  The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi‐allelic gene deletion , 2006, The Journal of pathology.

[255]  H. Li,et al.  Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells , 2006, Oncogene.

[256]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[257]  J. Derisi,et al.  Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant , 2006, PLoS pathogens.

[258]  R. Hayes,et al.  Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. , 2006, Journal of the National Cancer Institute.

[259]  R. Hill Identifying cancer stem cells in solid tumors: case not proven. , 2006, Cancer research.

[260]  Max S Wicha,et al.  Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.

[261]  S. Akira,et al.  Macrophage/Cancer Cell Interactions Mediate Hormone Resistance by a Nuclear Receptor Derepression Pathway , 2006, Cell.

[262]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[263]  Shunyou Wang,et al.  Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[264]  H. Wu,et al.  PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer , 2006, Oncogene.

[265]  P. Nelson,et al.  The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. , 2006, Cancer research.

[266]  O. Halvorsen,et al.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[267]  Aubie K. Shaw,et al.  Isolation and characterization of an immortalized mouse urogenital sinus mesenchyme cell line , 2005, The Prostate.

[268]  T. Sellers,et al.  Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans. , 2006, The Journal of urology.

[269]  P. Pandolfi,et al.  p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control. , 2006, Molecular and cellular biology.

[270]  T. Owen-Hughes,et al.  Nucleosome dynamics. , 2006, Biochemical Society symposium.

[271]  Ximing J. Yang,et al.  The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. , 2006, Genes & development.

[272]  C. Sawyers,et al.  Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. , 2005, Cancer research.

[273]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[274]  R. Shah,et al.  CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro , 2005, Aging cell.

[275]  R. Cardiff,et al.  Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. , 2005, Cancer research.

[276]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[277]  Hong Wu,et al.  Expression Signature of the Mouse Prostate* , 2005, Journal of Biological Chemistry.

[278]  W. Figg,et al.  In vivo models of prostate cancer metastasis to bone. , 2005, The Journal of urology.

[279]  Anna Frolov,et al.  Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. , 2005, Cancer research.

[280]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[281]  P. Pandolfi,et al.  Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. , 2005, Genes & development.

[282]  T. DeWeese,et al.  Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. , 2005, Cancer research.

[283]  R. Caprioli,et al.  Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation , 2005, Development.

[284]  T. Tsuzuki,et al.  Immunohistochemical study of chromogranin A in Stage D2 prostate cancer. , 2005, Urology.

[285]  K. Tomer,et al.  Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.

[286]  T. H. van der Kwast,et al.  Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. , 2005, Cancer research.

[287]  J. Hsieh,et al.  Down-regulation of Human DAB2IP Gene Expression Mediated by Polycomb Ezh2 Complex and Histone Deacetylase in Prostate Cancer* , 2005, Journal of Biological Chemistry.

[288]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[289]  D. Moscatelli,et al.  Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[290]  O. Witte,et al.  The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[291]  Christoph Wülfing,et al.  Polycomb Group Protein Ezh2 Controls Actin Polymerization and Cell Signaling , 2005, Cell.

[292]  James A Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[293]  D. Gioeli Signal transduction in prostate cancer progression. , 2005, Clinical science.

[294]  Jayoung Kim,et al.  Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. , 2005, The Journal of clinical investigation.

[295]  J. Cigudosa,et al.  Immortalization of primary human prostate epithelial cells by c-Myc. , 2005, Cancer research.

[296]  D. Peehl Primary cell cultures as models of prostate cancer development. , 2005, Endocrine-related cancer.

[297]  E. Gelmann,et al.  Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. , 2005, Cancer research.

[298]  M. Sadar,et al.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. , 2005, The Journal of urology.

[299]  M. Sadar,et al.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 2. , 2005, The Journal of urology.

[300]  N. Joste,et al.  Association between cancer-free survival and telomere DNA content in prostate tumors. , 2005, The Journal of urology.

[301]  S. Kasper Survey of genetically engineered mouse models for prostate cancer: Analyzing the molecular basis of prostate cancer development, progression, and metastasis , 2005, Journal of cellular biochemistry.

[302]  Zhong Jiang,et al.  Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. , 2005, American journal of clinical pathology.

[303]  Michael Ittmann,et al.  Mutation of the androgen receptor causes oncogenic transformation of the prostate. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[304]  J. Kench,et al.  Lower levels of nuclear β‐catenin predict for a poorer prognosis in localized prostate cancer , 2005, International journal of cancer.

[305]  Rajvir Dahiya,et al.  Epigenetic changes in prostate cancer: implication for diagnosis and treatment. , 2005, Journal of the National Cancer Institute.

[306]  L. Capasso Antiquity of cancer , 2005, International journal of cancer.

[307]  C. Logothetis,et al.  Osteoblasts in prostate cancer metastasis to bone , 2005, Nature Reviews Cancer.

[308]  W. Nelson Prostate cancer prevention , 2007, The Journal of nutrition.

[309]  D. Ghosh,et al.  Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.

[310]  S. Horvath,et al.  Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer , 2004, Clinical Cancer Research.

[311]  Fred Saad,et al.  Nuclear Factor-κB Nuclear Localization Is Predictive of Biochemical Recurrence in Patients with Positive Margin Prostate Cancer , 2004, Clinical Cancer Research.

[312]  Yong Lin,et al.  A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[313]  Ingo K Mellinghoff,et al.  HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.

[314]  H. Grönberg,et al.  Genetic Analysis of the RNASEL Gene in Hereditary, Familial, and Sporadic Prostate Cancer , 2004, Clinical Cancer Research.

[315]  A. Mills,et al.  Role of p63 and basal cells in the prostate , 2004, Development.

[316]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[317]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[318]  Chawnshang Chang,et al.  Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. , 2004, Molecular endocrinology.

[319]  D. Hudson,et al.  Epithelial stem cells in human prostate growth and disease , 2004, Prostate Cancer and Prostatic Diseases.

[320]  J. Isaacs,et al.  Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells , 2004, Cancer Research.

[321]  M. Datta,et al.  Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[322]  D. Neal,et al.  CD133, a novel marker for human prostatic epithelial stem cells , 2004, Journal of Cell Science.

[323]  E. Montgomery,et al.  Telomere Length Abnormalities Occur Early in the Initiation of Epithelial Carcinogenesis , 2004, Clinical Cancer Research.

[324]  A. Ullrich,et al.  The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.

[325]  Daniel J Schaid,et al.  The complex genetic epidemiology of prostate cancer. , 2004, Human molecular genetics.

[326]  P. Beachy,et al.  Roles for Hedgehog signaling in androgen production and prostate ductal morphogenesis. , 2004, Developmental biology.

[327]  M. Rubin,et al.  Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004, Cancer Research.

[328]  D. Grignon Unusual subtypes of prostate cancer , 2004, Modern Pathology.

[329]  L. Lessard,et al.  Expression of NF‐κB in prostate cancer lymph node metastases , 2004 .

[330]  A. D. De Marzo,et al.  GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer , 2004, Journal of cellular biochemistry.

[331]  S. Balk,et al.  Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence , 2004, Journal of cellular biochemistry.

[332]  M. Washington,et al.  TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.

[333]  I. Thompson,et al.  The Prostate Cancer Prevention Trial: current status. , 2004, The Journal of urology.

[334]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[335]  M. Ittmann,et al.  Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia , 2004, The Prostate.

[336]  E. Latulippe,et al.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.

[337]  A. Maitra,et al.  Urological Survey UROLOGICAL ONCOLOGY: PROSTATE CANCER Hedgehog Signalling in Prostate Regeneration, Neoplasia and Metastasis , 2005 .

[338]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[339]  Jin-Tang Dong Chromosomal Deletions and Tumor Suppressor Genes in Prostate Cancer , 2004, Cancer and Metastasis Reviews.

[340]  J. Hornaday,et al.  Cancer Facts & Figures 2004 , 2004 .

[341]  O. Grace,et al.  Sonic hedgehog regulates prostatic growth and epithelial differentiation. , 2003, Developmental biology.

[342]  M. Ittmann,et al.  Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. , 2003, Cancer research.

[343]  Michael F. Clarke,et al.  Applying the principles of stem-cell biology to cancer , 2003, Nature Reviews Cancer.

[344]  C. Sawyers Will mTOR inhibitors make it as cancer drugs? , 2003, Cancer cell.

[345]  W. Isaacs,et al.  Human prostate cancer precursors and pathobiology. , 2003, Urology.

[346]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[347]  J. Carpten,et al.  Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. , 2003, Cancer research.

[348]  Mustafa Ozen,et al.  Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. , 2003, Cancer research.

[349]  O. Witte,et al.  In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[350]  D. Corey,et al.  Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. , 2003, Cancer research.

[351]  T. Graeber,et al.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.

[352]  A. Thomson,et al.  FGF-10 plays an essential role in the growth of the fetal prostate. , 2003, Developmental biology.

[353]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[354]  P. Kantoff,et al.  Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[355]  C. Harley,et al.  A novel telomerase template antagonist (GRN163) as a potential anticancer agent. , 2003, Cancer research.

[356]  R. Cardiff,et al.  Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. , 2003, Cancer research.

[357]  J. Schalken,et al.  Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. , 2003, Critical reviews in oncology/hematology.

[358]  E. Gelmann Searching for the gatekeeper oncogene of prostate cancer. , 2003, Critical reviews in oncology/hematology.

[359]  Todd R. Golub,et al.  Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[360]  Tsuey-Ming Chen,et al.  Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model , 2003, The Prostate.

[361]  A. Evans,et al.  Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma , 2003, Oncogene.

[362]  Patricia D. Castro,et al.  Cellular senescence in the pathogenesis of benign prostatic hyperplasia , 2003, The Prostate.

[363]  W. Isaacs,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Pathological and Molecular Aspects of Prostate Cancer Prostate Cancer Ii , 2022 .

[364]  Jeffrey A. Magee,et al.  Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. , 2003, Cancer cell.

[365]  Rajvir Dahiya,et al.  Hormonal, cellular, and molecular control of prostatic development. , 2003, Developmental biology.

[366]  N. Greenberg,et al.  Models of metastatic prostate cancer: a transgenic perspective , 2003, Prostate Cancer and Prostatic Diseases.

[367]  Mitchell D Schnall,et al.  Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. , 2002, Cancer cell.

[368]  B. Foster,et al.  Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. , 2002, Differentiation; research in biological diversity.

[369]  J. Witte,et al.  RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases , 2002, Nature Genetics.

[370]  J. Hicks,et al.  Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. , 2002, Cancer research.

[371]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[372]  W. Bushman,et al.  Sonic hedgehog activates mesenchymal Gli1 expression during prostate ductal bud formation. , 2002, Developmental biology.

[373]  R. Cardiff,et al.  Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. , 2002, Cancer research.

[374]  C. Foster,et al.  Prostatic stem cells , 2002, The Journal of pathology.

[375]  R. Vessella,et al.  Establishment and characterization of osseous prostate cancer models: Intra‐tibial injection of human prostate cancer cells , 2002, The Prostate.

[376]  R. Cardiff,et al.  Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. , 2002, Cancer research.

[377]  Jing Ma,et al.  Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function. , 2002, Cancer research.

[378]  J. Trent,et al.  α-methylacyl-CoA racemase: A new molecular marker for prostate cancer , 2002 .

[379]  D. Troyer,et al.  Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[380]  Peter A. Humphrey,et al.  Conditional Loss of Nkx3.1 in Adult Mice Induces Prostatic Intraepithelial Neoplasia , 2002, Molecular and Cellular Biology.

[381]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[382]  R. Cardiff,et al.  Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[383]  D. Bostwick,et al.  Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer † , 2002, Genes, chromosomes & cancer.

[384]  K. Klinger,et al.  Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 , 2002, Nature Genetics.

[385]  M. Egorin,et al.  Androgen-Independent Prostate Cancer , 2002 .

[386]  R. V. van Breemen,et al.  Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. , 2001, Journal of the National Cancer Institute.

[387]  S. Hayward,et al.  Malignant transformation in a nontumorigenic human prostatic epithelial cell line. , 2001, Cancer research.

[388]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[389]  I. Leav,et al.  Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[390]  C. Korch,et al.  TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. , 2001, Cancer research.

[391]  J. Isaacs,et al.  Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. , 2001, Cancer research.

[392]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[393]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[394]  D. Ornstein,et al.  Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. , 2001, The Journal of urology.

[395]  J. Carpten,et al.  Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. , 2001, American journal of human genetics.

[396]  L. Marnett,et al.  Oxidative stress in chemoprevention trials. , 2001, Urology.

[397]  M. Kelley,et al.  Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[398]  Jianfeng Xu,et al.  Linkage of prostate cancer susceptibility loci to chromosome 1 , 2001, Human Genetics.

[399]  P. Chaurand,et al.  A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. , 2001, Cancer research.

[400]  K. Pienta,et al.  VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.

[401]  P. Roy-Burman,et al.  Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation , 2001, Mechanisms of Development.

[402]  P. Pandolfi,et al.  Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.

[403]  R. Dahiya,et al.  Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system , 2001, Cell Death and Differentiation.

[404]  L. Kolonel Fat, meat, and prostate cancer. , 2001, Epidemiologic reviews.

[405]  O. Kallioniemi,et al.  Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. , 2000, Cancer research.

[406]  R. Cardiff,et al.  Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. , 2000, Cancer research.

[407]  A. Bilancio,et al.  Steroid‐induced androgen receptor–oestradiol receptor β–Src complex triggers prostate cancer cell proliferation , 2000, The EMBO journal.

[408]  N. Copeland,et al.  Nkx3.1, a murine homolog of Drosophila bagpipe, regulates epithelial ductal branching and proliferation of the prostate and palatine glands , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[409]  M. Shen,et al.  Molecular genetics of prostate cancer. , 2000, Genes & development.

[410]  A. Whittemore,et al.  Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[411]  M. Benson,et al.  Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. , 2000, Urology.

[412]  D. Bostwick,et al.  Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer , 2000, Cancer.

[413]  L. Chung,et al.  LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis , 2000, The Prostate.

[414]  H. Arnold,et al.  Targeted disruption of the Nkx3.1 gene in mice results in morphogenetic defects of minor salivary glands: parallels to glandular duct morphogenesis in prostate , 2000, Mechanisms of Development.

[415]  Donna M. Peehl,et al.  Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor , 2000, Nature Medicine.

[416]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[417]  P. Hein,et al.  Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium , 2000, Breast Cancer Research.

[418]  J. Epstein,et al.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.

[419]  A. Belldegrun,et al.  Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. , 1999, Cancer research.

[420]  D. Bostwick,et al.  Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. , 1999, Journal of the National Cancer Institute.

[421]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[422]  L. Chin,et al.  Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.

[423]  M. T. Abreu-Martin,et al.  Mitogen-Activated Protein Kinase Kinase Kinase 1 Activates Androgen Receptor-Dependent Transcription and Apoptosis in Prostate Cancer , 1999, Molecular and Cellular Biology.

[424]  J. Clemens,et al.  Prostate development requires Sonic hedgehog expressed by the urogenital sinus epithelium. , 1999, Developmental biology.

[425]  R. Cardiff,et al.  Roles for Nkx3.1 in prostate development and cancer. , 1999, Genes & development.

[426]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[427]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[428]  H. Frierson,et al.  Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.

[429]  Jeremy Fairbank,et al.  Historical Perspective , 1984, Language in Society.

[430]  Desok Kim,et al.  Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.

[431]  D. Bostwick,et al.  Independent origin of multiple foci of prostatic intraepithelial neoplasia , 1998, Cancer.

[432]  M. Diaz,et al.  Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). , 1998, The Journal of urology.

[433]  F. Collins,et al.  Evidence for a prostate cancer susceptibility locus on the X chromosome. , 1998, Nature Genetics.

[434]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[435]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[436]  M. Ittmann,et al.  Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[437]  N. Maitland,et al.  Precise microdissection of human prostate cancers reveals genotypic heterogeneity. , 1998, Cancer research.

[438]  M. Kattan,et al.  Androgen-independent prostate cancer progression in the TRAMP model. , 1997, Cancer research.

[439]  M. Augustus,et al.  Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. , 1997, Cancer research.

[440]  J. Macoska,et al.  Allelic loss of 8p sequences in prostatic intraepithelial neoplasia and carcinoma. , 1997, Urology.

[441]  D. Bostwick,et al.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.

[442]  J Isola,et al.  Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.

[443]  R L Vessella,et al.  Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[444]  L. Liotta,et al.  Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. , 1996, Cancer research.

[445]  G. Buchanan,et al.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[446]  D. S. Coffey,et al.  Telomerase activity: a prevalent marker of malignant human prostate tissue. , 1996, Cancer research.

[447]  L. Liotta,et al.  Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. , 1995, Cancer research.

[448]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[449]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[450]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[451]  P. Scardino,et al.  The new american joint committee on cancer and international union against cancer tnm classification of prostate cancer , 1994, Cancer.

[452]  J. Moul,et al.  Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.

[453]  T Shiraishi,et al.  The frequency of latent prostatic carcinoma in young males: the Japanese experience. , 1994, In vivo.

[454]  T. Wheeler,et al.  Heterogeneity of prostate cancer in radical prostatectomy specimens. , 1994, Urology.

[455]  D. Grignon,et al.  High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. , 1994, In vivo.

[456]  P. Ruck,et al.  Neuroendocrine Differentiation in: Hepatoblastoma An Immunohistochemical Investigation , 1990, The American journal of surgical pathology.

[457]  G. Stemmermann,et al.  Latent prostatic carcinoma: pathological and epidemiological aspects. , 1989, Japanese journal of clinical oncology.

[458]  D. Bostwick,et al.  Prostatic intraepithelial neoplasia (PIN). , 1989, Urology.

[459]  J. McNeal,et al.  Normal histology of the prostate. , 1988, The American journal of surgical pathology.

[460]  S. J. Higgins,et al.  The endocrinology and developmental biology of the prostate. , 1987, Endocrine reviews.

[461]  R. Santen,et al.  Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement , 1987, The Prostate.

[462]  G. Evans,et al.  Cell proliferation studies in the rat prostate: II. The effects of castration and androgen‐induced regeneration upon basal and secretory cell proliferation , 1987, The Prostate.

[463]  D. S. Coffey,et al.  Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. , 1981, Cancer research.

[464]  J. McNeal The zonal anatomy of the prostate , 1981, The Prostate.

[465]  J. E. Dunn Cancer epidemiology in populations of the United States--with emphasis on Hawaii and California--and Japan. , 1975, Cancer research.

[466]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[467]  J. McNeal,et al.  Origin and development of carcinoma in the prostate , 1969, Cancer.

[468]  W. Haenszel,et al.  Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. , 1968, Journal of the National Cancer Institute.

[469]  J. Bailar,et al.  The histology and prognosis of prostatic cancer. , 1967, The Journal of urology.

[470]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.